Midkine ( MK ), a heparin binding growth factor, and cyclooxygenase -2 ( COX -2 ), a key enzyme in the conversion of arachidonic acid to prostaglandin, are both up -regulated at the mRNA or protein level in many human malignant tumors. Here, we investigated the tumor specificity of both MK and COX -2 promoters in human pancreatic cancer, with the aim to improve the selectivity of therapeutic gene expression. We constructed recombinant adenoviral ( Ad ) vectors containing either the luciferase ( Luc ) reporter gene under the control of the COX -2 or MK promoter or the herpes simplex virus thymidine kinase ( HSV Tk ) gene under the control of the COX -2 promoter and compared the expression with the cytomegalovirus ( CMV ) promoter. AdMKLuc achieved moderate to relatively high activity upon infection to both primary and established pancreatic carcinoma cells. Of the two COX -2 promoter regions ( COX -2M and COX -2L ), both revealed a high activity in primary pancreatic carcinoma cells, whereas in the established pancreatic carcinoma cell lines, COX -2L has an approximately equal high activity compared to CMV. In addition, both AdCOX -2M Tk and AdCOX -2L Tk induced marked cell death in response to ganciclovir ( GCV ) in three of four established pancreatic carcinoma cell lines. From these results, and because it has been reported that AdMKTk and AdCOX -2L Tk in combination with GCV did not reveal significant liver toxicity, we conclude that the MK as well as the COX -2 promoters are promising tumor -specific promoters for Ad vector -based gene therapy of pancreatic cancer. Cancer Gene Therapy ( 2001 ) 8, 990 -996 
P
ancreatic cancer is the fifth leading cause of cancer death in the Western world. Despite improvement in operative mortality rates, little impact has been made on the overall 5 -year survival. 1 Conventional chemotherapeutic intervention appears to be poorly effective in the treatment of pancreatic cancer and there is only marginal survival benefit from the latest generation of drugs. 1 Therefore, development of new therapeutic methods, such as gene therapy, is necessary to improve patient outcome and serve as a more effective treatment for pancreatic cancer. Adenoviral (Ad ) vectors have been used for both in vitro and in vivo gene delivery of pancreatic cancers. 2, 3 However, as observed for other tumor tissue types, a major concern associated with using Ad vectors in pancreatic carcinoma cells is the relatively limited transduction efficiencies achieved in vitro. 2 One of the approaches to overcome the inefficient delivery to pancreatic carcinoma cells is the use of infectivity enhanced Ad vectors, which bind to alternative cellular receptors and have been endeavored as a means to improve its specificity and efficacy. 4 -6 As a next step, we wanted to develop systems to express therapeutic genes selectively in pancreatic carcinoma cells using Ad vectors as a requisite for cancer gene therapy. Thus, we have been seeking for promoters that are ''on'' in pancreatic tumors and are ''off'' in the liver. The liver, especially, is the predominant site of Ad vector localization after systemic administration 7 and, as a consequence, is at risk when Ad vectors ectopically express therapeutic genes localized to this site. Whereas a number of promoters have been explored in the context of gene therapy for pancreatic cancer, i.e., the carcinoembryonic antigen promoter, 8 few exhibit the optimal activity in the context of specificity in pancreatic carcinoma.
Recently, it became known that two proteins, the heparinbinding growth /differentiation factor midkine (MK ) and the enzyme cyclooxygenase -2 (COX -2), appeared to be expressed in high levels in several types of human cancer. 9, 10 MK is a product of a retinoic acid -responsive gene and belongs to the new family of heparin -binding growth / differentiation factors that is induced by retinoic acid in embryonal carcinoma cells. 9 MK is expressed at higher levels in a number of human tumors, such as Wilms' tumors, 11 but also in breast, 12 hepatocellular, gastric, pancreatic, and colon carcinomas, 13 compared to corresponding normal tissues. Of interest, the human MK promoter has been cloned and identified 14 and appeared to be a candidate tumor-specific promoter for Wilms' tumor or neuroblastoma, 15 whereas no expression is observed in human liver. 11, 16 The other protein of interest, COX -2, is the key enzyme in the conversion of arachidonic acid to prostaglandins and other eicosanoids, and its action is inhibited by nonsteroidal antiinflammatory drugs. 17, 18 Recent studies have revealed that COX -2 expression is up -regulated in a variety of human cancers, including colon, 10 gastric, 19 esophageal, 20 and pancreatic cancer.
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The 5 0 control region of the COX -2 gene has been cloned and identified. 22, 23 Recently, the COX -2 promoter has been characterized in an Ad vector and was shown to be active in a majority of gastrointestinal cancers, whereas expression in the liver was strongly reduced, thus mitigating hepatotoxicity. 24 On this basis, we wanted to investigate whether COX -2, as well as MK, are potential candidate promoters for specific activity in pancreatic tumors, and compare it with the activity of the cytomegalovirus (CMV ) promoter. To analyze these promoters in Ad context, we inserted two regions of the COX -2 promoter, as well as one region of the MK promoter, into the deleted E1 region of the Ad5 vector and used to drive expression of either the luciferase ( Luc ) reporter or herpes simplex virus thymidine kinase (HSV Tk ) genes. In this study, we show that MK and COX -2 promoters are specific and have a high activity to achieve selective gene therapy in both primary and established pancreatic carcinoma cells.
MATERIALS AND METHODS

Cell lines
The established human pancreatic carcinoma cell lines ( BxPC -3, Capan-1, Hs766 -T, and MIA PaCa -2; > 20 passages) were purchased from Boehringer Ingelheim, Verviers, Belgium. The low passage (primary ) human pancreatic carcinoma cells (p6.3 and p10.5; <5 passages ) were obtained from Dr. E. Jaffee ( Johns Hopkins University School of Medicine, Baltimore, MD ). KATO III cells ( gastric carcinoma ) and LS174T cells ( colon carcinoma ) were purchased from the American Type Culture Collection ( Manassas, VA ). KATO III cells were cultured with RPMI 1640 (Mediatech, Herndon, VA ) with 20% fetal bovine serum ( FBS; Summit Biotechnology, Ft. Collins, CO ), 1% L -glutamine, and 1% penicillin /streptomycin ( Life Technologies, Rockville, MD ) streptomycin at 378C in 5% carbon dioxide atmosphere at 95% humidity. The other cells were cultured at the same conditions, but in this case, Dulbecco's minimal essential medium ( DMEM ) (Mediatech ) with 10% FBS is used.
Adenovirus vectors
The E1
À -and E3 À -deleted adenovirus vector expressing the firefly luciferase gene from the CMV immediate early promoter, AdCMVLuc, 25 was obtained from Dr. R. Gerard ( University of Leuven, Leuven, Belgium ). AdCMV-HSVTk, expressing the HSV Tk gene, was constructed as described earlier. 26 AdCMV GFP was obtained from Dr. Ramon Alemany (Gene Therapy Center, University of Alabama, Birmingham, AL ). The human MK promoter region containing 27 bp of exon 1 and 2285 bp of the 5 0 flanking region of the human MK gene was cloned into Ad vectors, as described. 15 Two control regions of the COX -2 promoters, the cox -2 M region (from À 883 to + 59 bp ) and the cox-2 L region ( from À 1432 to + 59 bp ) were cloned into Ad vectors as described. 24 Both promoters were derived from plasmid phPE52 as provided by Drs. Inoue and Tanabe at the National Cardiovascular Center Research Institute, Japan. 22, 23 The recombinant Ad vectors AdCOX -2M Luc and AdCOX -2L Luc, as well as AdCOX -2M Tk and AdCOX -2L Tk, under the control of human COX -2M and COX -2L promoter regions, respectively, and the recombinant Ad vectors AdMKLuc, under the control of the MK promoter, were constructed using the ''AdEasy'' method, reported previously. 27 Briefly, the COX -2M, COX -2L, and MK promoters 15 with the luciferase gene (plasmid pGL3; Promega, Madison, WI ) and the COX -2M and COX -2L promoters with the Tk gene 24 were inserted into a multiple cloning site in the pShuttle vector. 27 The resultant plasmid was linearized with PmeI digestion and subsequently cotransfected into Escherichia coli BJ5183 with pAdEasy-1 Ad backbone plasmid. After selection of recombinants in these bacteria, the recombinant of interest was grown up and linearized with PacI digestion and transfected into 293 cells to generate AdCOX -2M Luc, AdCOX -2L Luc, AdCOX -2M Tk, AdCOX -2L Tk, and AdMKLuc. The recombinant adenoviruses were propagated in 293 cells, purified by double CsCl density centrifugation, and virus titers were determined by plaque assay, as described. 28 
Adenovirus vector -mediated gene transfer
To assess the activity of the promoters in Ad context, 5Â10 4 of each of the tumor cells per well was plated in 24 -well plates and allowed to adhere overnight. The next day, the cells were infected with AdCOX -2M Luc, AdCOX -2L Luc, AdMKLuc, or AdCMVLuc at a multiplicity of infection (MOI) of 1, 10, and 100 per cell in phosphate -buffered saline (PBS ) for 1 hour at 378C. Cells were incubated in PBS without virus as a control. The virus was removed and the cells were incubated for 48 hours in complete media. The infected cells were harvested and treated with 100 L of lysis buffer (Cell Culture Lysis Buffer; Promega ). A luciferase assay ( Luciferase Assay System; Promega) and a Berthold luminometer ( Lumat, Wallc ) were used for the evaluation of luciferase activities of Ad -infected cells. Luciferase activities were normalized by the protein concentration in the cell lysate using the BCA Protein Assay procedure ( Pierce, San Francisco, CA ), as described by the manufacturer. 
Specific cell killing with Tk expression in Ad vectors
Tumor cells were plated in 96-well plates in triplicate at a density of 3000 cells / well. After overnight culture, cells were infected with AdCOX -2M Tk, AdCOX -2L Tk, AdCMVTk, and AdCMVGFP as control at an MOI of 500 for 5 hours. Because the cells were infected in a large infection volume ( 100 L ), the infections were performed at this relatively high MOI. The viral infection was followed by medium replacement including various concentrations of ganciclovir ( GCV ) ranging from 0 to 10,000 M. The number of surviving cells was determined by a 3 -( 4,5-dimethylthiazol-2 -yl )-2,5 -diphenyltetrazolium bromide ( MTT ) assay (CellTiter 96 Aqueous Nonradioactive Cell Proliferation Assay; Promega) after 5-day exposure of GCV using an automated Emax spectrophotometric plate reader ( Molecular Device, Sunnyvale, CA ). The depicted results are the mean of triplicate assays, and the standard deviation was assessed on basis of the three determinations.
RESULTS
The MK promoter region in Ad context has high activity in pancreatic carcinoma
To assess the usefulness of the MK promoter for pancreatic cancer, we investigated whether this promoter in an Ad context would manifest high transcriptional efficiency in both primary as well as in established pancreatic carcinoma cells. To this end, in a reporter gene experiment with firefly luciferase, these pancreatic carcinoma cells were infected with AdMKLuc or AdCMVLuc at MOIs of 1, 10, and 100 ( Fig 1 ) . In both primary pancreatic carcinoma cells ( p6.3 and p10.5), AdMKLuc showed relatively high Luc activity ( Fig 1A and B ) , approximately 30 -70% of the activity shown by AdCMVLuc at MOIs of 1 and 10, and approximately 10% of the activity with AdCMVLuc at an MOI of 100 ). In the four established pancreatic carcinoma cell lines, the luciferase activity induced by AdMKLuc showed moderate to high activity ( Fig 1C -F ) , approximately 10%, 25%, 25%, and 85% of the activity with AdCMVLuc for the Capan -1, BxPC -3, MIA PaCa -2, and Hs766-T cells, respectively (Fig 1C -F) . As a negative control for MK, the colon cancer cell line LS174T infected with AdMKLuc showed less than 1% luciferase activity compared with AdCMVLuc ( Fig 1G ) . These data indicated that the MK promoter is an attractive candidate for tumorspecific gene delivery in pancreatic cancer, as has been reported for pediatric tumors, with the ultimate advantage of strongly reduced activity in the liver. 1.0E+05
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1.0E+09 primary and in established pancreatic carcinoma cells, we decided to use two control regions of the COX -2 promoter ( COX -2M and COX -2L) to obtain more fidelity. Primary and established human pancreatic carcinoma cells were infected with AdCOX -2M Luc, AdCOX -2L Luc, or AdCMVLuc at MOIs of 1, 10, and 100 ( Fig 2) . In the primary pancreatic carcinoma cells (p6.3 and p10.5 ), luciferase activity induced by both AdCOX -2M as well as AdCOX -2L revealed high activity, approximately the same activity induced by the AdCMVLuc infection. Interestingly, virtually no difference of this high luciferase activity between the two COX -2 promoter constructs (COX -2M and COX -2L ) is observed (Fig 2A and B ) . In the four established pancreatic carcinoma cell lines ( BxPC -3, Capan-1, Hs 766T, and MIA PaCa -2), the luciferase activity induced by AdCOX -2M and AdCOX -2L also showed this high activity, but interestingly, in this case, AdCOX -2L has approximately 50 -80% of the luciferase activity induced by AdCMVLuc infection, whereas AdCOX -2M showed 20 -30% of the activity induced by AdCMVLuc infection (Fig 2C -F ) . The gastric cancer cell line KATO III, which is negative for COX -2 expression, was infected with AdCOX -2M and AdCOX -2L, revealing less than 1% luciferase activity compared with AdCMVLuc ( Fig  2G ) . In comparison with results of tumor-specific promoters published previously, 8 the luciferase activity induced by the COX -2 promoter regions in human pancreatic tumors as depicted in Figure 2 can be regarded as high and, therefore, the use of especially the COX -2L promoter region looks promising for tumor-specific gene therapy approaches in pancreatic carcinoma.
Effect of COX -2 promoter in combination with Tk and GCV in pancreatic carcinoma cells
To determine whether Ad -mediated infection with the COX -2M Tk and COX -2L Tk gene would render the four pancreatic carcinoma cell lines sensitive to cell killing by GCV, these cell lines as well as a control tumor cell line ( gastric cancer, KATO III ) were infected with AdCOX -2M Tk, AdCOX -2L Tk, AdCMVTk, or AdCMVGFP. After the recombinant Ad infection followed by 5 days of incubation with various concentrations of GCV, the number of surviving cells was determined by an MTT assay ( Fig 3) . Both AdCOX -2M Tk as well as AdCOX -2L Tk virus vectors successfully induced GCV sensitivity in the BxPC -3 and MIA PaCa -2 pancreatic carcinoma cell lines with IC 50 values ( the GCV concentration at which 50% cell survival is seen ) comparable to those obtained with the AdCMVTk virus. In BxPC -3 for AdCOX -2L Tk, AdCOX -2M Tk, and AdCMVTk, the IC 50 values are 8.3, 8.1 and 5.8 M GCV, respectively, whereas in MIA PaCa-2, the IC 50 values are 8.3, 6.1 and 5.8 M GCV, respectively ( Fig 3A and D ) . For the pancreatic carcinoma cell line Hs766 -T and the gastric cancer cell line KATO III, the induced GCV sensitivity by the AdCOX -2M Tk or AdCOX -2L Tk viruses was much less than that seen with AdCMV Tk. Here, in Hs766-T for AdCOX -2L Tk, AdCOX -2M Tk, and AdCMVTk, the IC 50 values are 850, 410 and 9.8 M GCV, respectively, whereas in KATO III, WESSELING, YAMAMOTO, ADACHI, ET AL: MIDKINE AND CYCLOOXYGENASE-2 PROMOTERS the IC 50 values are 55, 42 and 6.1 M GCV, respectively ( Fig 3C and E ) . Although the luciferase study revealed that both the COX -2M and COX -2L promoter activities were comparable with the CMV promoter activity in the Capan-1 cells (Fig 2D ) , the GCV sensitivity caused by AdCOX -2M /2L Tk /GCV was very limited. Because the sensitivity with AdCMVTk was also limited, this was thought to be caused by the relative resistance of the Capan-1 cells for GCV (Fig 3B ) . The data revealed that AdCOX -2M /2L Tk induced marked cell death in response to GCV in two of four pancreatic carcinoma cell lines, suggesting that the COX -2 promoter in combination with Tk and GCV might be a promising candidate for tumor-specific suicide gene therapy of human pancreatic tumors.
DISCUSSION
Human pancreatic carcinoma cells have been shown to be relatively resistant to adenovirus gene transfer, 2 but the use of both epidermal growth factor receptor (EGFR ) -targeted Ad vectors as well as integrin -targeted (i.e., RGD (ArgGly-Asp )-modified ) Ad vectors has demonstrated enhanced gene transfer to both primary as well as established pancreatic carcinoma cells. 4 -6 To investigate the tumorspecific potential of therapeutic gene expression in pancreatic cancer, here we showed for the first time that the MK promoter as well as the two COX -2 promoter regions in the Ad backbone revealed tumor-specific expression in both primary as well as established human pancreatic carcinoma cells. Furthermore, experiments with the Tk gene driven by the COX -2 promoter regions clearly indicate that this promoter may be an ideal candidate for tumor-specific suicide gene therapy of pancreatic cancer. Thus, both promoters revealed selective expression in pancreatic cancer by using two different transgenes (luciferase and HSV-Tk ). The discrepancy that the pancreatic tumor cell line Hs766-T showed similar luciferase expression for each of the two COX -2 promoters (COX -2L and COX -2M; Fig 2E ) , whereas differences between these promoter regions were observed in the cell killing assay by Tk in combination with GCV for this cell line (Fig 3 ) , may be explained by the observation that the specificity of the promoter regions varies with distinctive transgenes. 24, 29 Because for human pancreatic cancer current conventional therapies are inadequate or show a poor response, the high level of activity of AdCOX -2 Tk in pancreatic carcinoma cell lines suggests that this approach may offer new therapeutic options for this disease. In this regard, Tucker et al reported that COX -2 expression is up -regulated in human pancreatic cancer tissue both at the mRNA and at the protein level. Levels of COX -2 mRNA were increased by more than 60-fold in pancreatic cancer compared to adjacent nontumorous tissue, whereas immunoblotting revealed that COX -2 protein was present in 9 of 10 cases of adenocarcinoma of the pancreas, but was undetectable in nontumorous pancreatic tissue. 21 Yip -Schneider et al 30 confirmed the upregulation of the COX -2 protein expression in primary human pancreatic adenocarcinoma compared with normal pancreatic tissue by immunoblotting, and Okami et al, 31 who examined the distribution and extent of COX -2 protein in human pancreatic tumors using immunohistochemistry, showed moderate to strong expression of COX -2 protein in 47 of 52 pancreatic carcinomas.
The relatively high levels of expression of COX -2 and MK in pancreatic tumors will have a significantly enhanced therapeutic window compared to the use of viral promoters such as CMV. From the results of our study, it appeared that the COX -2L promoter region revealed a more profound tumor-specific activity in pancreatic carcinoma than the COX -2M promoter, which fits nicely with the observed reduced expression of this promoter region in normal human liver as described by Yamamoto et al, 24 and as also has been shown for the MK promoter. 15 The observation that the MK À and COX -2 promoters are virtually ''off'' in the liver confirmed the mitigation of hepatotoxicity upon AdMK Tk / GCV and AdCOX -2 Tk / GCV administration as reported for the AdCMVTk /GCV approach. 15, 24 The finding that the COX -2 and MK promoter regions revealed a luciferase activity comparable as induced by the CMV promoter in both primary and in established pancreatic carcinoma cells, is important because most tumor-specific promoters that have been proposed for use in gene therapy vectors previously exhibit levels of activity that are much lower than viral promoters. 8 This has led to the development of amplification strategies to enhance the efficiency of these specific but weak promoters. 32, 33 Furthermore, a number of candidate tumor-specific promoters have lost a significant part of their specificity when cloned in the Ad backbone, 34 probably due to cis -or trans -acting enhancing elements in the genome of the Ad vector. In this study, however, both MK and COX -2 promoters retain their activity and specificity in the Ad context.
In this study, we clearly demonstrate that the COX -2 and MK promoters are two promising candidate tumor-specific promoters in the context of Ad vectors, and they show moderate to high activity in both primary and established human pancreatic carcinoma cells. Furthermore, in vivo studies by Yamamoto et al, who intravenously administered AdCOX -2L Luc, AdCOX -2M Luc and AdCMV Luc in mice and determined the activity of the COX -2 promoters in liver and other major organs, showed that in the liver, the luciferase activity of AdCOX -2M Luc was 400-fold less than that with AdCMV Luc, whereas the luciferase activity of AdCOX -2L Luc was even 30,000 -fold less than with AdCMV Luc. 24 Therefore, for both COX -2 promoters ( especially the COX -2L ), remarkable reduction of the transgene expression in the liver was observed, leading to successful mitigation of hepatotoxicity. Combined with the targeted Ad vectors as described previously, 4 -6 the COX -2 and MK promoters may play an important role in transcriptional targeting of pancreatic cancer, which will certainly contribute to an improved gene therapeutic approach for this disease.
